Supplementary Figure S2 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Chand, Dhan; Savitsky, David A.; Krishnan, Shanmugarajan; Mednick, Gabriel; Delepine, Chloe; Garcia-Broncano, Pilar; Soh, Kah Teong; Wu, Wei; Wilkens, Margaret K.; Udartseva, Olga; Vincent, Sylvia; Joshi, Bishnu; Keith, Justin G.; Manrique, Mariana; Marques, Marilyn; Tanne, Antoine; Levey, Daniel L.; Han, Haiyong; Ng, Serina; Ridpath, Jackson; Huber, Olivia; Morin, Benjamin; Galand, Claire; Bourdelais, Sean; Gombos, Randi B.; Ward, Rebecca; Qin, Yu; Waight, Jeremy D.; Costa, Matthew R.; Sebastian-Yague, Alvaro; Rudqvist, Nils-Petter; Pupecka-Swider, Malgorzata; Venkatraman, Vignesh; Slee, Andrew; Patel, Jaymin M.; Grossman, Joseph E.; Wilson, Nicholas S.; Von Hoff, Daniel D.; Stebbing, Justin; Curiel, Tyler J.; Buell, Jennifer S.; O’Day, Steven J.; Stein, Robert B.

doi:10.1158/2159-8290.27938667

Supplementary Figure S2 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

journal contribution

posted on 2024-12-02, 08:41 authored by Dhan Chand, David A. Savitsky, Shanmugarajan Krishnan, Gabriel Mednick, Chloe Delepine, Pilar Garcia-Broncano, Kah Teong Soh, Wei Wu, Margaret K. Wilkens, Olga Udartseva, Sylvia Vincent, Bishnu Joshi, Justin G. Keith, Mariana Manrique, Marilyn Marques, Antoine Tanne, Daniel L. Levey, Haiyong Han, Serina Ng, Jackson Ridpath, Olivia Huber, Benjamin Morin, Claire Galand, Sean Bourdelais, Randi B. Gombos, Rebecca Ward, Yu Qin, Jeremy D. Waight, Matthew R. Costa, Alvaro Sebastian-Yague, Nils-Petter Rudqvist, Malgorzata Pupecka-Swider, Vignesh Venkatraman, Andrew Slee, Jaymin M. Patel, Joseph E. Grossman, Nicholas S. Wilson, Daniel D. Von Hoff, Justin Stebbing, Tyler J. Curiel, Jennifer S. Buell, Steven J. O’Day, Robert B. Stein

This dataset presents comparative results demonstrating the enhanced efficacy of Fc-enhanced anti-CTLA-4 versus the parental anti-CTLA-4 antibody in various tumor-bearing mouse models. Data from multiple tumor-bearing mouse models, strengthens the generalizability of the findings across different tumor types. The individual mouse data allows for a detailed view of treatment responses, including, variability within treatment groups, timing and rate of tumor growth or regression and potential identification of exceptional responders or non-responders.

History

ARTICLE ABSTRACT

This study reveals that Fc-enhanced anti–CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti–CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immuno-oncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.